For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Bempedoic acid - Lipid modification
PAD Profile : Bempedoic acid - Lipid modification
Traffic Light Status
Status 1 of 1.
- Tablets
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Atorvastatin
- Rosuvastatin calcium
- Simvastatin
- Ezetimibe
- Pravastatin sodium
- Fluvastatin sodium
- Evolocumab
- Alirocumab
- Simvastatin with fenofibrate
- Fenofibrate
- Bezafibrate
- Ciprofibrate
- Gemfibrozil
- Colesevelam hydrochloride
- Colestyramine
- Bempedoic acid with ezetimibe
- Inclisiran
- Icosapent
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a GREEN traffic light status for bempedoic Acid with ezetimibe in line with NICE guidance (TA694).
Please follow the guidance in the SPC and the National Lipid Management pathway for advice on initial and onward monitoring requirements.
Note: Anaemia is a common side-effect of bempedoic acid. For patients where a reduction in haemoglobin (Hb) may be of concern, consider a full blood count (FBC) at 3 months and annually thereafter.